Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity

BACKGROUND: Disease relapse remains common following treatment of acute myeloid leukemia (AML) and is due to chemoresistance of leukemia cells with disease repopulating potential. To date, attempts to define the characteristics of in vivo resistant blasts have focused on comparisons between leukemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Mark S., Basma, Naseer J., Amaral, Fabio M. R., Wiseman, Daniel H., Somervaille, Tim C. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554867/
https://www.ncbi.nlm.nih.gov/pubmed/34711181
http://dx.doi.org/10.1186/s12885-021-08839-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554867/
https://www.ncbi.nlm.nih.gov/pubmed/34711181
http://dx.doi.org/10.1186/s12885-021-08839-9

Ejemplares similares